Teva Pharmaceutical Industries stock targets $7B in 2030 innovation revenue

Teva Pharmaceutical Industries Ltd. outlined a long-term expansion plan at its first R&D Day on Wednesday, November 11, targeting 6 to 7 billion US dollars in annual revenue from innovative medicines by 2030. The company also expects total revenue to grow at a mid-single-digit rate from 2026 through 2030.

The plans were detailed in a GlobeNewswire release carried by The Manila Times. President and CEO Richard Francis said Teva had more than doubled innovative medicines revenue since launching its Pivot to Growth strategy in 2023.

Pipeline and margin expansion

Teva said innovative medicines now account for more than 20% of revenue, while gross margin has improved to about 55%. The company cited seven late-stage pipeline assets and ten programs overall, including two clinical antibodies discovered internally.

The company plans to use its research platform and commercial infrastructure to support the potential launch of one innovative medicine annually through 2030. Teva also pointed to its AUSTEDO, AJOVY and UZEDY franchises, which it expects to grow by more than 125% by the end of 2026.

Longer-term financial targets

Beyond innovative-medicine revenue, Teva set a target of more than 3.5 billion US dollars in free cash flow by 2030. Management also said the pipeline has more than 10 billion US dollars in non-risk-adjusted peak-sales potential, while noting that development and regulatory approval remain necessary for investigational products.

US market conditions remain relevant for Teva's New York Stock Exchange listing. Current market reports